β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
1. A method for the treatment of a hepatitis B infection in a human, said method comprising administering an effective amount of 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt thereof, of the formula:
wherein R is selected from the group consisting of, (C═O)-alkyl, (C═O)-aryl, (C═O)-alkoxyalkyl, (C═O)-aryloxyalkyl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, and a stabilized nucleotide or nucleoside prodrug, wherein the stabilized nucleotide or nucleoside prodrug is a 5′- or N 6 -alkylated derivative, a 5′-phospholipid, or a 5′-ether lipid.
2. The method of claim 1 , wherein the amino acid is L-valinyl.
3. A method for the treatment of a hepatitis B infection in a human, said method comprising administering an effective amount of a combination of the compounds
or a combination of the compounds
or a combination of the compounds
wherein R is selected from the group consisting of
H, (C═O)-alkyl, (C═O)-aryl, (C═O)-alkoxyalkyl, (C═O)-aryloxyalkyl alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, and a stabilized nucleotide or nucleoside prodrug wherein the stabilized nucleotide or nucleoside prodrug is a 5′- or N 6 -alkylated derivative, a 5′-phospholipid, or a 5′-ether lipid.
4. The method of claim 3 , wherein the amino acid is L-valinyl.
5. A method for the treatment of a hepatitis B infection in a human, said method comprising administering an effective amount of
in combination or alternation with an additional anti-hepatitis B agent,
wherein R is selected from the group consisting of,
(C═O)-alkyl, (C═O)-aryl, (C═O)-alkoxyalkyl, (C═O)-aryloxyalkyl alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, mono, di, and triphosphate, and a stabilized nucleotide prodrug, wherein the stabilized nucleotide or nucleoside prodrug is a 5′- or N 6 -alkylated derivative, a 5′-phospholipid, or a 5′-ether lipid
and wherein the additional anti-hepatitis B agent is selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosine-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC), β-L-2″-fluoro-5-methyl-arabinafuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil), 9-((1R,2R,3S0-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir, and ribavarin.
6. The method of claim 5 , wherein the amino acid is L-valinyl.
7. A pharmaceutical composition comprising an effective amount of a compound or pharmaceutically acceptable salt thereof of the formula:
wherein R is selected from the group consisting of, (C═O)-alkoxyalkyl, (C═O)-aryloxyalkyl alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid acyl residue, and a stabilized nucleotide or nucleoside prodrug, wherein the stabilized nucleotide or nucleoside prodrug is a 5′-phospholipid, or a 5′-ether lipid; in combination with an anti-hepatitis B agent selected from the group consisting of β-L-2-hydroxymethyl-5-(cytosine-1-yl)-1,3-oxathiolane (3TC), cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC), β-L-2′-fluoro-5-methyl-arabinofuranosyluridine (L-FMAU), β-D-2,6-diaminopurine dioxolane (DAPD), famciclovir, penciclovir, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475), 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil), 9-((1R,2R,3S0-2,3-bis(hydroxymethyl)cyclobutyl)guanine (lobucavir), ganciclovir, and ribavarin;
in combination with a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7 wherein R is L-valinyl.